Clinical Trial Update: NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating NB1011 infused continuously in cancers overexpressing thymidylate synthase has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Tumor

Drugs mentioned

• NB1011

Snippet

Sponsor: Kiadis Pharma | Conditions: Tumors | Phase 1, Phase 2 | Status: COMPLETED